UNSPSC 51261504: Cetamolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H26N2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5UNK5C6QM5, chemically known as 2-(2-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenoxy)-n-methylacetamide monohydrochloride but more generally known as cetamolol hydrochloride, which bears US NIH Compound Identifier 53697. Most nations, for tariff and trade purposes, schedule cetamolol hydrochloride under HS 29242995 and SITC 51479.

As of Q4 2014, CETAMOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cetamolol hydrochloride bears US NLM identifiers UMLS ID C2825713 and NCI Concept Code C81652. SMILES: CC(C)(C)NCC(COC1CCCCC1OCC(=O)NC)O.CL.

UNSPSC 51261504 Cetamolol hydrochloride is a Commodity code that nominally describes a specific beta-blocker pharmaceutical, but recent state and local solicitation activity shows little alignment with this narrow product definition. The single relevant opportunity on record—Seminole County, Florida's IFB60459723LAS—actually targets naloxone and drug deactivation systems for community health support, not cetamolol. A second opportunity, the Texas Health and Human Services Commission's RFI HHS0017013, addresses direct-to-manufacturer prescription program strategy and vendor capabilities, which likewise does not correspond to procurement of a specific pharmaceutical commodity. The code shows no recent state or local activity genuinely focused on cetamolol hydrochloride procurement.

Seminole County's July 2026 naloxone bid (IFB60459723LAS, due July 26, 2026) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and a fixed-fee contract structure with a two-year initial term and one-year renewal option. Texas HHS's April 2026 RFI (HHS0017013) functioned as exploratory market intelligence regarding direct-to-manufacturer prescription relationships and did not constitute a binding procurement. The mismatch between the code's nominal scope and actual recent solicitation activity suggests that either the code has been misapplied to these opportunities or that state and local procurement offices are not actively acquiring cetamolol hydrochloride under this taxonomy category at present.